论文部分内容阅读
吉利德科学(Gilead Sciences)公司近日公布了一项名为POSITRON的Ⅲ期临床研究结果,该项研究旨在评价多聚酶抑制剂sofosbuvir(曾用代号:GS-7977)用于基因2或3型慢性丙型肝炎患者的疗效。参加该项研究的受试患者为对干扰素不耐受或不
Gilead Sciences recently released a Phase III clinical trial called POSITRON that evaluated the use of the sofosbuvir inhibitor (formerly code: GS-7977) for chronic type 2 or 3 chronic Hepatitis C patients. The subjects who participated in the study were either not well tolerated or not interferon